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Background
T-VEC is a herpes simplex virus-1-based oncolytic
immunotherapy designed to selectively replicate in
tumors, produce GM-CSF, and stimulate antitumor
immune responses. OPTiM, a Phase III trial of T-VEC vs
GM-CSF in unresectable stage IIIB-IV melanoma,
improved the primary endpoint of durable response rate
(DRR) in the T-VEC arm (16 vs 2%).[1] Pembrolizumab,
a human programmed death receptor-1 (PD-1)-blocking
antibody approved for the treatment of advanced meta-
static or unresectable melanoma, has demonstrated
superiority over the CTLA-4-blocking antibody ipilimu-
mab in patients with stage III or IV melanoma that
received no more than one prior line of systemic therapy
(PFS HR 0.58, OS HR 0.63-0.69).[2] Combining T-VEC
with pembrolizumab may enhance antitumor immune
responses vs either therapy alone. Here, we describe a
Phase Ib/III study assessing the safety and efficacy of
T-VEC + pembrolizumab in unresected stage IIIB-IV
melanoma. Twenty-one patients enrolled in Phase Ib
December 2014 through March 2015 at 11 institutions in
Australia, Spain, Switzerland, and the United States.
Methods
Primary objective for Phase Ib: assess dose-limiting toxi-
cities of T-VEC + pembrolizumab. Key secondary objec-
tives for Phase Ib: best OR, DRR, duration of response,
disease control rate, PFS by investigator using modified
immune-related response criteria (irRC), OS, treatment-
emergent/related AEs, and potential blood/tumor bio-
markers for response/resistance to combination treat-
ment. Key eligibility criteria for Phase Ib: stage IIIB-IV
melanoma naïve to systemic treatment (except adju-
vant), injectable lesions, ECOG PS 0-1, no active cere-
bral metastases, no autoimmunity/immunosuppression,
and no active herpetic infection. In Phase Ib, T-VEC is
injected into cutaneous, subcutaneous, or nodal lesions
at up to 4 mL of 106 plaque forming units (PFU)/mL
day 1, then at up to 4 mL of 108 PFU/mL day 22 and
Q2W. Pembrolizumab is given 200 mg IV Q2W. Treat-
ment with both therapies continues until (whichever
comes first): CR or PD per irRC, intolerance, for up to
2 yrs or, for T-VEC, when there are no longer injectable
lesions. The randomized portion of the study comparing
T-VEC + pembrolizumab to pembrolizumab alone was
originally designed as a Phase II study. An updated
Phase III design will be presented.
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